EWING, NJ--(Marketwire - November 15, 2007) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) to provide additional means to characterize the immunogenic protein subunit component of RiVax™, the company's preventive vaccine against ricin toxin. The CRADA will be carried out at the Division of Biochemistry at WRAIR and will encompass basic studies to reveal the underlying protein structure that is important in inducing human immune responses to ricin toxin. Ricin toxin is an easy to manufacture toxin that poses a serious threat as a bioweapon, primarily by inhalation.
